Schrödinger

Headlines · 2

1. 4d
   Simcere president takes IT department under direct control, mandates AI use

   36Kr reports that Simcere Pharmaceutical president Zhou Yunshu brought the company's information department under his direct management in 2026 and said at a recent media briefing that managers are required, not merely encouraged, to embrace AI in their work. The company embedded AI engineers into business units so that AI could gradually move from an auxiliary tool to a basic function across target discovery, clinical work, drug manufacturing, marketing and operations, and in July 2026 Simcere signed a drug discovery and development collaboration with US AI drug discovery company Schrödinger. The report also notes that for pharma companies without an AI-native background, measuring AI's actual value remains difficult, and that Simcere spent a large number of tokens on early exploration.

   36氪 人工智能 · 🔥 0
2. Oct 9
   Over $3B floods into 'physical AI' for science as AI drug discovery hits limits

   An article republished by 36Kr from 动脉网 tallies more than $3B in direct and indirect funding over the past year or so into "physical AI" for AI4S — systems that let AI operate instruments and robots in real wet labs. It names Medra, 津渡生科, 术也科技, 合碳智能, 宇道生物, 予路乾行, 深度细胞, Phyraxis AI and Transfyr, alongside NVIDIA's joint lab with Eli Lilly, a Simcere–Schrödinger drug discovery deal and Anthropic's open MHS model-hardware standard with HHMI Janelia. The piece argues AI drug discovery's bottleneck is no longer algorithms or compute but wet-lab data and hardware, with failed-experiment data locked inside companies creating a structural mismatch.

   36氪 人工智能 · 🔥 0

Experience and discussion from the community

Share my Schrödinger experienceAsk about Schrödinger